Hsa-miR-375 is a predictor of local control in early stage breast cancer

Clinical Epigenetics

Table 2 Follow-up and clinical outcome

Clinical outcome
Parameters		Pilot phase n = 32		Validation phase n = 115
Parameters		Relapse n = 16	Control n = 16	Relapse n = 30	Control n = 85
Time to local relapse (months)	Median	37	x	74	x
Time to local relapse (months)	Range	15–123	x	35–185	x
Time to distant metastasis (months)	Median	61	x	70	49.5
Time to distant metastasis (months)	Range	20–96	x	27–118	9–109
Follow-up (months)	Median	121.5	130.5	125	140
	Range	26–192	72–200	44–214	17–207
	Lost to follow-up (n)	0	0	0	1 (1.2 %)
Cancer specific deaths (n)		4 (25 %)	0	7 (23.3 %)	2 (2.4 %)

ISSN: 1868-7083